Replies to post #3096 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

…I don't buy the tax selling as a root cause.

Neither do I. What has had greater impact, IMO, is selling by those who expected a quick buyout after the first FDA approval and became disenchanted when it didn’t happen. Some of these investors may not appreciate the magnitude of RVNC’s upside from therapeutic indications.

[vinmantoo]

Is this really about a slow ramp up, bad market, lost faith in management, or combination of all of the above? Beats me. We're trading as if approval never happened, and it's really hard to understand why. Even slow launch seems hard to back as a reason because market is always forward looking, One possibility, which I hope is untrue, is that my assumptions about company aren't true/realistic, someone else already knows this now based on launch feedback, but tragically, I won't until later

I can't control what others think of Daxxi's prospects. I do know that sales will begin to ramp up in the first half of 2023 and RVNC won't have to raise cash. In my view we must be close to a bottom so the only things in question are how rapidly sales will ramp up, will Daxxi get approval for other indications (e.g. CD), and will there be a buyout. These are all positives in my view so I feel buying now is pretty well de-risked.